← Eichor
Study identifier: NCT07299591 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Analysis of Pharmacological Aspects Regarding Infection Free Survival After Surgical Treatment of a Periprosthetic Hip Infection: a Microdialysis Study

Condition: Periprosthetic Hip Infection  ·  Sponsor: University Hospital, Bonn

PhaseN/A
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to use the technique of microdialysis to analyse the intraarticular space of the hip joint after removal of a periprosthetic joint infection affected endoprosthesis and implantation of an antibiotic-containing cement spacer over the entire period of the first hospitalization (usually 14 days) to closely monitor pharmacological and immunological aspects. In detail, antibiotic concentrations in the joint cavity and systemic circulation will be assessed according to reinfection rates, infection-free survival and fucntional outcome over a 12-month folluw-up period.

This description comes directly from the study's public registry record.

Talk to the study team

Alexander Franz, Dr. med., B. Sc.  ·  +491703750718  ·  alexander.franz@ukbonn.de

Julika Behrens  ·  +4915752849422  ·  julika.behrens@ukbonn.de

Always discuss trial participation with your own doctor first.

Locations (1)

University Hospital BonnBonn, North Rhine-Westphalia, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07299591